Inozyme Pharma Inc expected to post a loss of 36 cents a share - Earnings Preview

Inozyme Pharma

03/05/2024 16:51

* Inozyme Pharma Inc  INZY.OQ   INZY.O  is expected to show
no
change in quarterly revenue when it reports  results on May 7
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Inozyme Pharma Inc is
for a
loss of 36 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $15.50​, above​ its last closing price of $4.65. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.34       -0.32      -0.33     Missed  -3.6
 Sep. 30 2023  -0.31       -0.32      -0.29     Beat    8.3
 Jun. 30 2023  -0.40       -0.43      -0.35     Beat    19.2​
 Mar. 31 2023  -0.44       -0.45      -0.40     Beat    10.3
 ​​Dec.        -0.42       -0.45      -0.42     Beat    7
 31 2022                                                
 Sep. 30 2022  -0.43       -0.43      -0.38     Beat    12.5​
 Jun. 30 2022  -0.48       -0.48      -0.38     Beat    20.6
 Mar. 31 2022  -0.82       -0.82      -0.71     Beat    13.6
 This summary was machine generated May 3 at 15:51 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)